Biotech | August 02, 2021
Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The group now has 320 approvals and has so far filed over 400 ANDAs
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
Subscribe To Our Newsletter & Stay Updated
